Current surveillance data shows no SARS-CoV-2 lineage has met Variant of Concern criteria in 2026, with dominant strains like XFG and its sublineages remaining Omicron descendants that have not demonstrated major shifts in transmissibility, severity, or immune escape beyond prior waves. BA.3.2, designated a Variant Under Monitoring by the WHO in December 2025 after detections in multiple countries, reached notable shares in parts of Europe but stays at low U.S. prevalence with minimal impact on hospitalizations. Widespread population immunity from vaccination and prior infections continues to limit the potential for a highly disruptive new variant, while genomic monitoring has detected no signals warranting escalation. Traders assign an 85% probability to no new Variant of Concern before 2027 based on this stable trajectory and the absence of recent concerning developments.